Discontinuation symptoms in depression and anxiety disorders
Discontinuation symptoms in depression and anxiety disorders
The present overview investigates whether different antidepressants have differing discontinuation symptoms upon treatment cessation, if these symptoms vary between depression and anxiety disorders, and with length of treatment. Data came from two comparative studies of escitalopram in major depressive disorder (MDD) (one vs. venlafaxine XR and one vs. paroxetine), two studies in social anxiety disorder (SAD) (one of which used paroxetine as the active reference), and one study in generalized anxiety disorder (GAD), using paroxetine as an active reference [total number of patients: escitalopram (n = 1051); paroxetine (n =336); venlafaxine XR (n = 124); placebo (n = 239)]. All studies included a defined discontinuation period and used the Discontinuation Emergent Signs and Symptoms (DESS) checklist to record the number of discontinuation symptoms. All three antidepressants showed more discontinuation symptoms compared with placebo (p < 0.001). Patients reported significantly fewer discontinuation symptoms with escitalopram than with paroxetine and venlafaxine XR in MDD (p < 0.05). Escitaloprarn showed significantly fewer discontinuation symptoms than paroxetine in SAD (p < 0.05) and GAD (p < 0.001). For each antidepressant, no differences in discontinuation symptoms were observed between the three indications and there was no evidence for increased symptom incidence with increased length of treatment. Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment
escitalopram, venlafaxine, extended-release, generalized anxiety disorder, paroxetine, double-blind, panic disorder, citalopram, disorders, affective disorders, discontinuation effects, gad, social anxiety disorder, major depressive disorder, prevention, interruption, antidepressant, placebo
73-84
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Montgomery, S.A.
8b3324f3-c514-4f9d-9c33-6af1824da849
Nil, R.
36398c1b-1d82-4871-96e6-a5e401313ff7
Lader, M.
24f6301f-080d-452e-be88-7f528a99f3b9
2007
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Montgomery, S.A.
8b3324f3-c514-4f9d-9c33-6af1824da849
Nil, R.
36398c1b-1d82-4871-96e6-a5e401313ff7
Lader, M.
24f6301f-080d-452e-be88-7f528a99f3b9
Baldwin, D.S., Montgomery, S.A., Nil, R. and Lader, M.
(2007)
Discontinuation symptoms in depression and anxiety disorders.
International Journal of Neuropsychopharmacology, 10 (1), .
(doi:10.1017/S1461145705006358).
Abstract
The present overview investigates whether different antidepressants have differing discontinuation symptoms upon treatment cessation, if these symptoms vary between depression and anxiety disorders, and with length of treatment. Data came from two comparative studies of escitalopram in major depressive disorder (MDD) (one vs. venlafaxine XR and one vs. paroxetine), two studies in social anxiety disorder (SAD) (one of which used paroxetine as the active reference), and one study in generalized anxiety disorder (GAD), using paroxetine as an active reference [total number of patients: escitalopram (n = 1051); paroxetine (n =336); venlafaxine XR (n = 124); placebo (n = 239)]. All studies included a defined discontinuation period and used the Discontinuation Emergent Signs and Symptoms (DESS) checklist to record the number of discontinuation symptoms. All three antidepressants showed more discontinuation symptoms compared with placebo (p < 0.001). Patients reported significantly fewer discontinuation symptoms with escitalopram than with paroxetine and venlafaxine XR in MDD (p < 0.05). Escitaloprarn showed significantly fewer discontinuation symptoms than paroxetine in SAD (p < 0.05) and GAD (p < 0.001). For each antidepressant, no differences in discontinuation symptoms were observed between the three indications and there was no evidence for increased symptom incidence with increased length of treatment. Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment
This record has no associated files available for download.
More information
Published date: 2007
Keywords:
escitalopram, venlafaxine, extended-release, generalized anxiety disorder, paroxetine, double-blind, panic disorder, citalopram, disorders, affective disorders, discontinuation effects, gad, social anxiety disorder, major depressive disorder, prevention, interruption, antidepressant, placebo
Identifiers
Local EPrints ID: 62278
URI: http://eprints.soton.ac.uk/id/eprint/62278
ISSN: 1461-1457
PURE UUID: 5e1ad9e9-0db7-48b3-97c4-777b80b6ffc4
Catalogue record
Date deposited: 11 Sep 2008
Last modified: 16 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
S.A. Montgomery
Author:
R. Nil
Author:
M. Lader
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics